Regulation of cancer cell proliferation by caveolin-2 down-regulation and re-expression

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1395-1402

  Lee, Sangho ^a   Kwon, Hayeong ^a   Jeong, Kyuho ^a   Pak, Yunbae ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

Cancer progression; Caveolin 2; Proliferation; Transcriptional activation

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 AZA 2' DEOXYCYTIDINE; CAVEOLIN 2; LUCIFERASE; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR ELK 1;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOMA CELL; CELL ASSAY; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MALE; NEUROBLASTOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPORTER GENE; TRANSCRIPTION INITIATION; UTERINE CERVIX CANCER;

ANIMALS; CAVEOLIN 2; CELL PROLIFERATION; DOWN-REGULATION; ETS-DOMAIN PROTEIN ELK-1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOMA; HEP G2 CELLS; HUMANS; NEOPLASMS; NEUROBLASTOMA; RATS; STAT3 TRANSCRIPTION FACTOR;

EID: 79955018193     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.958     Document Type: Article

References (47)

1. Chu C, Kohtz DS and Lisanti MP: Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 271: 15160-15165, 1996. (Pubitemid 26197582)
2. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P and Lisanti MP: Cell-type and tissue-specific expression of caveolin-2. J Biol Chem 272: 29337-29346, 1997.
3. Navarro A, Anand-Apte B and Parat MO: Arole for caveolae in cell migration. FASEB J 18: 1801-1811, 2004.
4. Williams TM and Lisanti MP: Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: C494-C506, 2005. (Pubitemid 40229478)
5. Parton RG and Simons K: The multiple faces of caveolae. Nat 5. Rev Mol Cell Biol 8: 185-194, 2007.
6. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS and Lisanti MP: Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. Arole for the caveolin-scaffolding domain. FEBS Lett 428: 205-211, 1998.
7. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG and Lisanti MP: Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 275: 20717-20725, 2000. (Pubitemid 30457660)
8. Kim S and Pak Y: Caveolin-2 regulation of the cell cycle in response to insulin in Hirc-B fibroblast cells. Biochem Biophys Res Commun 330: 88-96, 2005. (Pubitemid 40394939)
9. Kwon H, Jeong K and Pak Y: Identification of pY19-caveolin-2 as a positive regulator of insulin-stimulated actin cytoskeleton-dependent mitogenesis. J Cell Mol Med 13: 1549-1564, 2009.
10. Kwon H, Jeong K, Hwang EM, Park JY and Pak Y: A novel domain of caveolin-2 that controls nuclear targeting: regulation of insulin-specific ERK activation and nuclear translocation by caveolin-2. J Cell Mol Med: DOI: 10.1111/j.1582-4934.2010.01079.x, 2010.
11. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, Chan SK, Jones SJ, Leung SP, Masoudi H, Leung S, Wiseman SM and Nabi IR: Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 68: 8210-8220, 2008.
12. Kerr J, Leary JA, Harst T, Shih YC, Antalis TM, Fridlander M, Crawford E, Khoo SK, Ward Band Chenevix-Trench G: Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus. Oncogene 13: 1815-1818, 1996.
13. Huang H, Qian C, Jenkins RB and Smith DI: Fish mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosomes Cancer 21: 152-159, 1998. (Pubitemid 28081242)
14. Ishwad CS, Ferrell RE, Hanley K, Davare J, Meloni AM, Sandberg AA and Surti U: Two discrete regions of deletion at 7q in uterine leiomyomas. Genes Chromosomes Cancer 19: 156-160, 1997. (Pubitemid 27278802)
15. Liang H, Fairman J, Claxton DF, Nowell PC, Green ED and Nagarajan L: Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci USA 95: 3781-3785, 1998. (Pubitemid 28173206)
16. Wang XL, Uzawa K, Miyakawa A, Shiiba M, Watanabe T, Sato T, Miya T, Yokoe H and Tanzawa H: Localization of a tumour-suppressor gene associated with human oral cancer on 7q31.1. Int J Cancer 75: 671-674, 1998. (Pubitemid 28145811)
17. Nishizuka S, Tamura G, Terashima M and Satodate R: Commonly deleted region on the long arm of chromosome 7 in differentiated adenocarcinoma of the stomach. Br J Cancer 76: 1567-1571, 1997. (Pubitemid 27520583)
18. Shridhar V, Sun QC, Miller OJ, Kalemkerian GP, Petros Jand Smith DI: Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas. Oncogene 15: 2727-2733, 1997. (Pubitemid 27507620)
19. Lee H, Park DS, Razani B, Russell RG, Pestell RG and Lisanti MP: Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 161: 1357-1369, 2002.
20. Hatanaka M, Maeda T, Ikemoto T, Mori H, Seya T and Shimizu A: Expression of caveolin-1 in human T cell leukemia cell lines. Biochem Biophys Res Commun 253: 382-387, 1998. (Pubitemid 29026712)
21. Hu YC, Lam KY, Law S, Wong J and Srivastava G: Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 7: 3519-3525, 2010.
22. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD and Thompson TC: Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61: 3882-3885, 2001. (Pubitemid 32720945)
23. Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuura N, Kakudo K, Kuma K and Miyauchi A: Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer 86: 912-916, 2002. (Pubitemid 34271027)
24. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs Gand Cordon-Cardo C: Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62: 6973-6980, 2002. (Pubitemid 35424089)
25. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D and Anderson KC: Essential role of caveolae in interleukin-6 and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 278: 5794-5801, 2003. (Pubitemid 36800825)
26. Engelman JA, Zhang XL and Lisanti MP: Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436: 403-410, 1998. (Pubitemid 28482971)
27. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG and Lisanti MP: Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. J Biol Chem 273: 20448-20455, 1998. (Pubitemid 28377612)
28. Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ and Li M: 28. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am J Clin Pathol 120: 93-100, 2003. (Pubitemid 37046375)
29. Wikman H, Seppänen JK, Sarhadi VK, Kettunen E, Salmenkivi K, Kuosma E, Vainio-Siukola K, Nagy B, Karjalainen A, Sioris T, Salo J, Hollmén J, Knuutila S and Anttila S: Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays. J Pathol 203: 584-593, 2004. (Pubitemid 38529039)
30. Jeong K, Kwon H, Min C and Pak Y: Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts. Exp Mol Med 41: 226-235, 2009.
31. Kwon H, Jeong K, Hwang EM, Park JY, Hong SG, Choi WS and Pak Y: Caveolin-2 regulation of STAT3 transcriptional activation in response to insulin. Biochim Biophys Acta 1793: 1325-1333, 2009.
32. Kwon H and Pak Y: Prolonged tyrosine kinase activation of insulin receptor by pY27-caveolin-2. Biochem Biophys Res Commun 391: 49-55, 2010.
33. Engelman JA, Zhang XL and Lisanti MP: Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett 448: 221-230, 1999.
34. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T and Brothman AR: Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46: 249-256, 2001. (Pubitemid 32142772)
35. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schäfer R and Sers C: Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159: 1635-1643, 2001. (Pubitemid 33062506)
36. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, Shay JW, Gazdar AF and Minna JD: Different roles for caveolin-1 in the development of non-small cell lung cancer versus small-cell lung cancer. Cancer Res 64: 4277-4285, 2004. (Pubitemid 38802434)
37. Mikol DD, Hong HL, Cheng HL and Feldman EL: Caveolin-1 expression in Schwann cells. Glia 27: 39-52, 1999. (Pubitemid 29311505)
38. Racine C, Bélanger M, Hirabayashi H, Boucher M, Chakir J, and Couet J: Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 255: 580-586, 1999. (Pubitemid 29294841)
39. Thomsen P, Roepstorff K, Stahlhut M and van Deurs B: Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol Cell 13: 238-250, 2002. (Pubitemid 34106072)
40. Kim J, Adam RM, Solomon KR and Freeman MR: Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 145: 613-619, 2004. (Pubitemid 38183803)
41. Silva WI, Maldonado HM, Velázquez G, Rubio-Dávila M, Miranda JD, Aquino E, Mayol N, Cruz-Torres A, Jardón J and Salgado-Villanueva IK: Caveolin isoform expression during differentiation of C6 glioma cells. Int J Dev Neurosci 23: 599-612, 2005. (Pubitemid 41464586)
42. Zhao X, Liu Y, Ma Q, Wang X, Jin H, Mehrpour M and Chen Q: Caveolin-1 negatively regulates TRAIL-induced apoptosis in human hepatocarcinoma cells. Biochem Biophys Res Commun 378: 21-26, 2009.
43. Cruzalegui FH, Cano E and Treisman R: ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene 18: 7948-7957, 1998. (Pubitemid 30050555)
44. Wierenga AT, Vogelzang I, Eggen BJ and Vellenga E: Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol 31: 398-405, 2003. (Pubitemid 36579365)
45. Lin MI, Yu J, Murata T and Sessa WC: Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res 67: 2849-2856, 2007. (Pubitemid 46548975)
46. Razani B, Schlegel A, Liu J and Lisanti MP: Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 29: 494-499, 2001. (Pubitemid 32783645)
47. Darnell JE: Validating Stat3 in cancer therapy. Nat Med 11: 595-596, 2005.